Drug Profile


Alternative Names: GENHP-01; GNN001

Latest Information Update: 21 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GeNeuro
  • Class Antihyperglycaemics; Immunotherapies; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Toll-like receptor 4 antagonists; Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Type 1 diabetes mellitus

Most Recent Events

  • 19 Jun 2017 GeNeuro plans to complete enrolment in its phase IIa RAINBOW-T1D trial in Type-1 diabetes mellitus in Australia by the end of 2017
  • 06 Jun 2017 Phase-II clinical trials in Type-1 diabetes mellitus in Australia (IV) (NCT03179423)
  • 24 Mar 2017 GeNeuro initiates the ANGEL-MS extension study for Multiple Sclerosis in Spain (EudraCT2016-004935-18)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top